Demonstrated profound safety of multiple intravenous doses of AAT therapy for treatment of newly diagnosed type 1 diabetes while maintaining glycemic control and less of a decrease in C-Peptide levelsץ
Baxalta will collaborate in the development and funding of the study, which will be conducted in Israel. The study is expected to initiate in the first half of 2016.
Additional analyses demonstrate that inhaled AAT is able to change the nature of exacerbations to events with fewer symptoms (statistically significant), a change that correlates with the benefit seen in lung function.
Data highlighted in panel discussion with renowned pulmonology experts who specialize in treating patients with alpha-1 antitrypsin deficiency will serve as basis for MAA submission in Europe
Introduces 2015 Revenue Guidance
Conference call begins today at 8:30 a.m. Eastern time
Dial in numbers for the conference call: USA: 186-629-702-42 or 188-854-512-12 Israel: 03-9180600 Conference Code: 76224# NESS ZIONA, Israel (May 8, 2015) – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three months ended March 31, 2015 prior to […]
Dial in numbers for the conference call: USA: 186-629-702-42 or 188-854-512-12 Israel: 03-9180600 Conference Code: 76224# NESS ZIONA, Israel (May 8, 2015) – Kamada Ltd. (NASDAQ and TASE: KMD), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three months ended March 31, 2015 prior to […]
Panel of Leading Pulmonologists to Discuss Potential New Treatment Option for Alpha-1 Antitrypsin Deficiency Patients
NESS ZIONA, Israel (April 28, 2015) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces executive management changes intended to strengthen the Company's leadership while benefitting from its accomplished executives and advancing its protein therapeutics platform. Under the changes, David Tsur, co-founder and Chief Executive Officer, will […]
Demonstrates efficacy in a variety of lung function measurements based on post hoc statistical analyses as recommended by EMA
NESS ZIONA, Israel (April 1, 2015) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the Company has received an allowance from the Canadian Intellectual Property Office (CIPO) for Patent Application No. 2,538,998 entitled, “Large Scale Preparation of Alpha-1 Proteinase Inhibitor and Use Thereof.” The allowed […]